Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05095727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: May 26, 2026 to Nov 30, 2026v20 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 45 to confirmed 15
    • Study completion date: Dec 26, 2028 to Nov 30, 2026
    • Site details revised at 16 of 16 sites
  2. Re-verified, no change to tracked fieldsv19
  3. Study sites: 10 to 16v18
  4. Primary completion date: Jan 7, 2026 to May 26, 2026
    • Eligibility criteria shortened, about 16 words
    v17
  5. Study sites: 9 to 10v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 8 to 9v15
  2. Phase: Phase 1 to Phase 1/2v14 Show 7 more changesShow less
    • Primary completion date: Oct 21, 2024 to Jan 7, 2026
    • Primary endpoint revised
    • Enrollment target: 33 to 45
    • Study completion date: Oct 21, 2025 to Dec 26, 2028
    • Eligibility criteria shortened, about 46 words
    • Secondary endpoints revised (8)
    • Study description expanded, about 1 word
  3. Study sites: 6 to 8v13
  4. Enrollment target: 18 to 33v12 Show 8 more changesShow less
    • Primary completion date: Jan 19, 2024 to Oct 21, 2024
    • Study sites: 7 to 6
    • Study completion date: Jan 19, 2024 to Oct 21, 2025
    • Eligibility criteria expanded, about 47 words
    • Secondary endpoints: 15 to 8
    • Study description expanded, about 10 words
    • Study arms: 1 to 2
    • Study title expanded, about 3 words
  5. Study sites: 6 to 7v11
  6. Study description shortened, about 4 wordsv10
  7. Study sites: 5 to 6
    • Eligibility criteria revised
    • Secondary endpoints: 11 to 15
    v9
  8. Start date changed from estimate of May 10, 2022 to Jun 1, 2022v8
  9. Start date: Mar 21, 2022 to May 10, 2022
    • Study sites: 3 to 5
    v7
  10. Study sites: 2 to 3v6
  11. Start date: Jan 28, 2022 to Mar 21, 2022
    • Study sites: 1 to 2
    v5
  12. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 17, 2022 to Jan 28, 2022
    • Site details revised
    v4
  13. Site contact updatedv3
  14. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.
Trial Details
NCT Number NCT05095727
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Glycogen Storage Disease
Related terms Genetic Diseases, Inborn, Glucose Metabolism Disorders, Glycogen Storage Disease, Glycogen Storage Disease Type I
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov